Graft-versus-host disease (GVHD) continues to be a serious complication that limits the success of allogeneic bone marrow transplantation (BMT). Using IL-7 deficient murine models, we have previously shown that IL-7 is necessary for the pathogenesis of GVHD.
Introduction
Graft-versus-host disease (GVHD) continues to be a limiting factor in the use of clinical hematopoietic stem cell transplantation (HSCT). GVHD occurs when donor T cells recognize host antigenic disparities expressed on antigen presenting cells (APC), resulting in activation of alloreactive T cells and destruction of host tissues. Patients with GVHD develop a wide range of symptoms including skin rash, diarrhea, liver disease, erythema, weight loss which eventually result in death (1-7). Immunosuppressive drug treatment or mature T cell depleted bone marrow transplantation (TCD BMT) have been used as effective strategies to prevent GVHD (8, 9) . However, these strategies can also lead to engraftment failure, a prolonged state of immune deficiency, and various types of opportunistic infections. Therefore, developing a therapeutic strategy to suppress GVHD without compromising the immune system will be ideal for allogeneic BMT recipients.
IL-7 and Kit ligand (KL, stem cell factor [SCF]), are the major lymphopoietic cytokines produced in the thymus and BM compartment (10) (11) (12) (13) . IL-7 induces proliferation, differentiation, and survival of immature T lymphocytes. During normal T cell development in the thymus, IL-7 produced by thymic epithelial cells (TECs) binds to the cognate IL-7 receptor (IL-7R). The IL-7R is comprised of IL-7Rα and common γ subunits and expressed on the surface of immature T lymphoid progenitor cells.
Mutations of the IL-7, IL-7Rα, and γc genes result in defective thymopoiesis and impaired ability to produce T lymphocytes (14) (15) (16) (17) (18) . Previously we and others have shown that administration of recombinant human IL-7 following histocompatible BMT in murine recipients corrects thymopoietic defects and enhances immune reconstitution, For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From further suggesting the importance of IL-7 in development of T lymphocytes (19) .
Besides its thymopoietic effects, IL-7 also promotes expansion and survival of mature naïve and memory CD4 + and CD8 + T cells. Recent studies have shown that IL-7/IL-7R interactions in concert with low-affinity interactions between T cell receptors (TCR) and self-peptide ligands bound to MHC allow proliferation of mature T cells in the periphery (20) (21) (22) (23) (24) (25) (26) . In addition, IL-7 enhances the survival of alloreactive donor T cells in allogeneic BMT recipients and plays a crucial role in the development and exacerbation of GVHD (27, 28, (30) (31) (32) .
Based on the effects of IL-7 on mature T cells, we investigated whether GVHD could be prevented by a blockade of IL-7Rα with an anti-IL-7Rα monoclonal antibody. Similar to earlier experimental results that we obtained from the genetic model of IL-7 deficiency, we demonstrated that anti-IL-7Rα antibody treatment can successfully prevent GVHD by eliminating donor mature T cells (27) . Paradoxically, anti-IL-7Rα
antibody treatment did not impair donor-derived thymopoiesis even though IL-7 is critical for the development of T cells. These results indicate that anti-IL-7Rα antibody treatment may be beneficial for prevention of GVHD. 
Bone marrow transplantation procedure
Female recipient H2K b C57BL/6J mice were given two separate doses of radiation (700 cGy on day -1 and 600 cGy on day 0) as previously described (27 
Administration of anti-IL-7Rα antibody
For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From 6 Anti-murine IL-7Rα antibody produced from the ST185 hybridoma clone (gift of Paul Kincade, University of Oklahoma) was purified using a Hi Trap Protein G HP antibody isolation kit (Amersham Biosciences, Uppsala Sweden). To test whether anti-IL-7Rα antibody treatment can prevent GVHD, allogeneic BMT plus LN recipients were subcutaneously injected weekly with either saline, nonspecific rat IgG (AbD Serotec, Raleigh, NC), or anti-IL-7Rα antibody (100 µg/ mouse) from day 0 for 4 weeks. The clinical status of the BMT recipients was evaluated using a GVHD scoring system as previously described (28) .
Cell Proliferation Assay
To test the anti-IL-7Rα antibody's ability to block IL-7R signaling, 3 H-thymidine incorporation assay was performed using the murine IL-7 dependent B cell line, 2E8
(ATCC, Manassas, VA). The 2E8 cell line was incubated with either freshly purified anti-IL-7Rα antibody (100 ng/ml) or non-specific IgG for 30 minutes and treated with rhIL-7 in various different concentrations for 24 hours to measure cell proliferation.
Assessment of GVHD
GVHD severity was assessed using the previously described clinical scoring system (28).
Each BMT recipient was scored weekly for five parameters (weight loss, skin integrity, fur texture, mobility, and posture), using a scale of 0 to 2, with 0 for absent or normal, 1 for mildly abnormal, and 2 for severely abnormal. The GVHD clinical index was the sum of the scores for individual criteria.
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Histologic analyses
Small intestine, skin, and thymic tissues were fixed in 10% formalin, embedded in parafin, and cut into 5 µm thick sections for H&E staining. Tissue sections were examined for evidence of GVHD. Immunohistochemical staining of thymic sections were done as previously described (29) 
Immunophenotyping
BMT recipients were sacrificed by CO 2 narcosis, and the thymus, spleen, and LN cells were removed. Single cell suspensions of each organ were prepared, and the total cell 
Sheep RBC (SRBC) Immunizations
Normal and recipient mice were immunized with SRBC (Colorado Serum Company, Denver, CO) via IP injection at day 44 post-BMT, as previously described (19) . After 2 weeks, peripheral blood was drawn for primary antibody responses against SRBC, and the mice were boosted with SRBC for secondary responses, which were measured one week later. The agglutination antibody titers in the serum were determined by serial dilution and incubation with SRBC in 96-well V-bottom microplates (Corning Inc, Corning, NY). 
Statistical analyses

Results
Decreased IL-7 dependent proliferation of 2E8 cell line by anti-IL-7Rα antibody
Since our previous data demonstrated that proliferation and maintenance of donorderived allogeneic mature T cells are reduced in the absence of IL-7, we investigated whether a blockade of IL-7R signaling by anti-IL-7Rα antibody treatment had similar effects (27) . To determine whether the anti-IL-7Rα antibody purified from the ST185 hybridoma supernatant binds to the murine IL-7Rα, lymph node T cells from a BALB/c mouse were incubated in vitro with the anti-IL-7Rα antibody. The purified anti-IL-7Rα antibody bound to both CD4 and CD8 T cells expressing IL-7Rα ( Figure 1A) . Next we performed a cell proliferation assay using the IL-7 dependent B cell line, 2E8 to determine if binding of anti-IL-7Rα antibody blocked IL-7 dependent proliferation.
After incubating the cell line in media that contains anti-IL-7Rα antibody (100 ng/ml), IL-7 was added and proliferative capacity was measured. Figure 1B shows that anti-IL-7Rα antibody can effectively prevent proliferation of the 2E8 cell line. These results demonstrate that anti-IL-7Rα antibody blocks IL-7R signaling and prevents IL-7 dependent cell proliferation in vitro.
Anti-IL-7Rα antibody treatment prevents GVHD related morbidity and mortality
To measure the efficacy of anti-IL-7Rα antibody treatment in the prevention of GVHD, antibody treatment reduces GVHD-related morbidity and mortality.
Prevention of GVHD-related tissue inflammation by anti-IL-7Rα antibody
To assess the effects of anti-IL-7Rα antibody on GVHD directly, GVHD-target organs were analyzed on day 30 after transplantation. Sections from the skin and small intestine were stained with H&E and assessed for histologic damage. The tissue samples from allogeneic BMT plus LN recipients treated with saline displayed histological evidence of GVHD. The skin samples showed lymphocytic infiltration, hyperkeratosis, and hair loss, and the intestines had villus blunting, lymphocytic infiltration, lamina propria inflammation, crypt destruction, and mucosal atrophy (Figure 3) . In contrast, tissue samples from anti-IL-7Rα treated allogeneic BMT plus LN recipients showed no histological evidence of GVHD and looked similar to those from normal, allogeneic, or congenic BMT recipients. These data provide evidence that anti-IL-7Rα treatment can prevent GVHD-related tissue damage and inflammation.
Decreased numbers of donor T cells in the periphery of anti-IL-7Rα antibody recipients
Since anti-IL-7Rα antibody treatment prevented GVHD, we investigated the effects of Fig. 2) .
To clarify the source of the T cells observed early after transplant, allogeneic TCD H2K 
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( Figure 5 ). Our data demonstrate that anti-IL-7Rα antibody treatment did not completely block proliferation of donor T cells. However, we observed that the frequency of proliferating donor T cells at day 10 in the presence of anti-IL-7Rα antibody was lower than that of saline treated recipients. The reduction of donor spleen and LN T cell numbers in anti-IL-7Rα antibody treated allogeneic BMT plus LN recipients is consistent with the lower incidence of GVHD-related mortality we observed (Figure 2A) .
Anti-IL-7Rα antibody treatment results in improves GVHD-related thymic atrophy
TECs are targets of GVHD in both clinical and experimental allogeneic BMT (33) (34) (35) .
Alloreactive donor T cells are known to damage the host thymic microenvironment. To investigate whether the improvement of donor-derived thymopoiesis following anti-IL-7Rα antibody treatment is solely caused by the suppression of alloreactivity rather Figure 4 ).
These results demonstrate that anti-IL-7Rα antibody treatment not only prevents GVHD, but also improves donor-derived thymopoiesis by suppression of alloreactivity.
Anti-IL-7Rα antibody treatment improved development of T cell dependent antibody responsiveness
Since anti-IL-7Rα antibody treatment preserved donor-derived thymopoiesis at day 30,
we then examined functional T cell dependent immunity by immunizing the transplanted recipients with sheep red blood cells (SRBC). The transplanted mice were immunized with SRBC on day 44 and the secondary boost was given two weeks after primary immunization (day 58). Following immunization, we measured primary and secondary antibody responses directed against SRBC. The saline treated allogeneic BMT and LN transplant group had low anti-SRBC titers after primary and secondary immunization (Figure 7) . In contrast, the anti-IL-7Rα antibody treated allogeneic BMT plus LN recipients displayed significantly higher secondary titers than the saline treated allogeneic BMT plus LN recipients, and titers in the anti-IL-7Rα antibody treated recipients were comparable to those observed in the normal and BMT only recipients. Although IL-7 was initially thought to regulate T and B lymphopoiesis, IL-7 signaling is also important for the peripheral expansion and survival of mature T cells (20) (21) (22) (23) (24) (25) (26) .
Adoptive transfer of naive congenic T lymphocytes into sub-lethally irradiated IL-7
-/-recipients results in minimal expansion of donor T cells, which could be restored by IL-7 administration (24) . In addition, IL-7 mediates homeostasis of CD4 and CD8 memory T cells in vivo (20) (21) (22) . IL-7 signaling also promotes survival of activated allogeneic donor fold less than that required to cross the thymus-blood barrier to deplete thymocytes (44) .
Following SRBC immunization, we observed that the response to a neo-antigen in anti-IL-7Rα antibody treated allogeneic BMT plus LN recipients was significantly greater than the saline treated allogeneic BMT plus LN recipients. It is likely that the improvement of T cell dependent humoral immunity in the anti-IL-7Rα treated recipients was caused by donor-derived naïve T lymphocytes generated from the recipient thymus. For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From
